KYMR Kymera Therapeutics, Inc.

Kymera Therapeutics, Inc. operates as a biotechnology company, which engages in curing untreatable diseases. It focuses on discovering and developing novel small molecule therapeutics. The firmís proprietary integrated degradation platform consists of informatics-driven target identification, novel E3 ligases and ligands, proprietary predictive modeling, and novel degradation tools. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

$55.13  +1.20 (2.23%)
As of 10/19/2021 15:59:59 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Mid cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  08/21/2020
Outstanding shares:  51,039,817
Average volume:  277,821
Market cap:   $2,919,477,532
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    501575104
ISIN:        US5015751044
Valuation   (See tab for details)
PE ratio:   -47.13
PB ratio:   9.46
PS ratio:   45.24
Return on equity:   -22.63%
Net income %:   -90.50%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy